TB Alliance Applauds WHO Prequalification of Taj Pharma’s Pretomanid 200mg Tablet

Taj Pharma Achieves Milestone with WHO Prequalification

Pretomanid 200mg Tablets Manufacturers PAN India, Suppliers
Pretomanid 200mg Tablets

Taj Pharma, a globally recognized pharmaceutical company headquartered in India, has achieved a landmark recognition with the World Health Organization (WHO) prequalification of its Pretomanid 200mg Tablet. This development marks a significant step forward in the global fight against drug-resistant tuberculosis (DR-TB), ensuring patients and healthcare providers worldwide can access a medicine that is proven for safety, efficacy, and quality.

Pretomanid, developed by the nonprofit TB Alliance, has been integrated into innovative treatment regimens such as BPaL and BPaLM, which reduce treatment timelines for DR-TB to just six months, compared to the traditional regimens that lasted 9–18 months or longer. This advancement provides new hope to patients facing one of the deadliest infectious diseases globally.

Pretomanid: A Game-Changer in DR-TB Treatment

Pretomanid 200mg is not just another addition to the global TB treatment arsenal. It is one of the three critical medicines used in the BPaL/M regimen—comprising bedaquiline, pretomanid, and linezolid (with or without moxifloxacin)—which has dramatically reshaped the landscape of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) treatment.

  • Shortened treatment duration: Six months instead of up to 24 months.
  • Improved patient adherence: Reduced pill burden enhances treatment compliance.
  • Higher efficacy: Demonstrated significant cure rates in clinical trials.
  • Global accessibility: With WHO prequalification, procurement for low- and middle-income countries (LMICs) is now possible through UN agencies and international funding bodies.

The Global Burden of Drug-Resistant Tuberculosis

Pretomanid 200mg Tablets Manufacturers India, Suppliers
Pretomanid 200mg Tablets

According to the latest WHO Global TB Report, an estimated 400,000 people developed DR-TB in 2023, but only 176,000 initiated treatment. This enormous treatment gap underscores the urgent need for innovative therapies like pretomanid to be accessible and affordable worldwide.

Tuberculosis remains the leading cause of death from an infectious disease, surpassing even HIV/AIDS. Despite decades of research and public health initiatives, the emergence of drug resistance has threatened progress and left millions vulnerable. With pretomanid now WHO-prequalified, Taj Pharma is positioned to close this gap and bring life-saving therapy to the patients who need it most.

Taj Pharma’s Commitment to Global Health

Taj Pharma has committed to commercialize pretomanid in nearly 140 countries and territories, strengthening the company’s role as a leader in addressing unmet healthcare needs. Through its strategic collaboration with TB Alliance, Taj Pharma is driving forward a sustainable and competitive market for TB medicines that prioritizes both affordability and accessibility.

Key highlights of Taj Pharma’s commitment:

  • Global reach: Distribution in countries across Asia, Africa, Latin America, and beyond.
  • Affordability focus: Ensuring low-cost access for LMICs through partnerships with UN procurement agencies like the Global Drug Facility (GDF) and The Global Fund.
  • Sustainability: Building a long-term supply chain infrastructure for TB medicines.
  • Innovation in manufacturing: WHO prequalification ensures that every batch of pretomanid adheres to international GMP (Good Manufacturing Practices) standards.

What WHO Prequalification Means for Pretomanid

Pretomanid 200mg Tablets Manufacturers India & Pioneer Exporters
Pretomanid 200mg Tablets (Afiniti)

WHO prequalification is not merely a technical endorsement; it is a gold standard certification that confirms a medical product meets rigorous standards of safety, quality, and efficacy. For pretomanid 200mg manufactured by Taj Pharma, this status means:

  1. Eligibility for procurement by UN agencies and major global health organizations.
  2. Streamlined regulatory approvals in many countries, accelerating patient access.
  3. Credibility and trust for healthcare providers prescribing pretomanid.
  4. Support for national TB programs in implementing shorter, effective regimens.

This recognition makes Taj Pharma a critical player in the worldwide distribution of TB medicines, further solidifying its reputation as a global pharmaceutical leader.

Strategic Partnership with TB Alliance

The collaboration between Taj Pharma and TB Alliance represents a new model of public-private partnership in global health. TB Alliance, which spearheaded the development of pretomanid, ensures that cutting-edge research is translated into accessible products, while Taj Pharma leverages its manufacturing expertise and distribution networks to scale access.

Through this partnership:

  • Pretomanid is being produced at scale with WHO-approved quality standards.
  • The medicine is reaching high-burden TB countries rapidly.
  • Taj Pharma supports the global TB elimination strategy by integrating pretomanid into national TB programs.

Addressing the Urgent Need for DR-TB Treatments

Pretomanid 200mg Tablets Manufacturer, Supplier in Vapi, Gujarat
Pretomanid 200mg Tablets

The introduction of pretomanid into global markets comes at a crucial time. With drug resistance on the rise, patients who previously faced lengthy, toxic, and often ineffective treatments can now complete therapy in six months, with far fewer side effects.

This advancement addresses key barriers to TB treatment:

  • Reduced stigma: Shorter regimens mean fewer workplace and social disruptions.
  • Increased cure rates: Pretomanid has demonstrated strong outcomes in clinical trials such as NIX-TB.
  • Equity in healthcare: Availability in 140+ countries ensures that low-income populations are not left behind.

Future Outlook: Taj Pharma’s Role in TB Elimination

The End TB Strategy, led by the WHO, aims to reduce TB deaths by 95% by 2035. To achieve this ambitious goal, access to innovative therapies like pretomanid is essential. Taj Pharma’s WHO-prequalified product strengthens the global TB response by:

  • Ensuring continuous availability of high-quality medicines.
  • Expanding global treatment coverage for DR-TB.
  • Supporting research-driven development of next-generation TB regimens.
  • Collaborating with governments, NGOs, and international agencies to deliver medicines at scale.

A Turning Point in the Fight Against TB

Leading Pretomanid 200mg Tablets Manufacturer & Supplier in India
Pretomanid 200mg Tablets

The WHO prequalification of Taj Pharma’s Pretomanid 200mg Tablet represents a historic milestone in global health. By bridging innovation with accessibility, Taj Pharma and TB Alliance are reshaping the way the world combats drug-resistant tuberculosis.

With a treatment regimen that is shorter, more effective, and now globally accessible, millions of lives stand to be saved in the coming years. This achievement underscores Taj Pharma’s enduring commitment to affordable healthcare, innovation, and international collaboration.

WHO Prequalification for Pretomanid 200mg Tablet, Expanding Global Access to DR-TB Treatment

Taj Pharma, one of India’s leading pharmaceutical manufacturers, has earned the prestigious World Health Organization (WHO) prequalification for its Pretomanid 200mg Tablet, marking a breakthrough in the global fight against drug-resistant tuberculosis (DR-TB). This milestone ensures patients and healthcare providers worldwide can access a medicine that meets the highest international standards of safety, quality, and efficacy.

Developed by the nonprofit TB Alliance, pretomanid is a key component of the BPaL and BPaLM regimens, which combine bedaquiline, pretomanid, linezolid (with or without moxifloxacin) to effectively treat DR-TB. Unlike traditional regimens that required 9–18 months of treatment, this innovative therapy reduces treatment duration to six months, improves patient adherence, and demonstrates superior cure rates.

According to WHO’s Global TB Report, nearly 400,000 people developed DR-TB in 2023, yet only 176,000 began treatment. Pretomanid addresses this urgent gap, offering hope to thousands of patients who previously faced limited options.

Through a strategic partnership with TB Alliance, Taj Pharma has committed to commercialize pretomanid in over 140 countries and territories, ensuring broad and affordable access. WHO prequalification allows procurement by major global health agencies such as the Global Fund and Stop TB’s Global Drug Facility, accelerating availability in low- and middle-income countries (LMICs) where the burden of TB remains highest.

This recognition not only strengthens Taj Pharma’s role as a global leader in pharmaceutical innovation, but also contributes directly to the WHO End TB Strategy, which aims to reduce TB deaths by 95% by 2035. By combining world-class manufacturing with a commitment to accessibility, Taj Pharma is helping reshape the future of drug-resistant TB treatment.